Sagimet Biosciences Inc. Quarterly Operating Income (Loss) in USD from Q2 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sagimet Biosciences Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2022 to Q2 2024.
  • Sagimet Biosciences Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$10.6M, a 50.1% decline year-over-year.
  • Sagimet Biosciences Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$36.3M.
  • Sagimet Biosciences Inc. annual Operating Income (Loss) for 2023 was -$30.7M, a 1.01% increase from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$36.3M -$10.6M -$3.53M -50.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$32.7M -$8.77M -$2M -29.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$30.7M -$9.47M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$7.45M +$234K +3.04% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$7.06M +$181K +2.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$6.77M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q3 2022 -$7.69M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$7.24M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.